Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Seres Therapeutics Inc (MCRB) Earnings: Report Dates and Results
Seres Therapeutics (MCRB) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Seres Therapeutics reported EPS of -$1.06, above the -$1.34 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MCRB has an expected report date of Mar 10, 2027.
MCRB Earnings Call
The latest MCRB earnings call transcript on file is labeled 2025Q3.
Read the 2025Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, MCRB beat 19, missed 17 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $593000, up 68.9% from $351000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.06 | -$1.34 | -$1.34 - -$0.67 | +20.90% | Beat | -212.8% | 2 | 0 up, 1 down | Nov 4, 2026 | $593000 |
| Jun 30, 2026 | -$1.50 | -$2.07 | -$2.30 - -$2.07 | +27.54% | Beat | N/A | 2 | 0 up, 0 down | Aug 5, 2026 | $736000 |
| Mar 31, 2026 | -$2.08 | -$1.88 | -$1.88 - -$1.88 | -10.64% | Miss | N/A | 1 | 0 up, 0 down | May 5, 2026 | $358000 |
| Dec 31, 2025 | -$1.76 | -$1.60 | -$1.60 - -$1.60 | -10.00% | Miss | N/A | 1 | 0 up, 1 down | Mar 12, 2026 | $438000 |
| Sep 30, 2025 | $0.94 | $0.05 | N/A | N/A | N/A | N/A | 1 | 1 up, 0 down | Nov 5, 2025 | $351000 |
| Jun 30, 2025 | -$2.27 | -$2.27 | -$2.60 - -$1.95 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Aug 6, 2025 | N/A |
| Mar 31, 2025 | -$2.24 | $1.97 | -$2.40 - $5.60 | -213.71% | Miss | N/A | 3 | 0 up, 0 down | May 7, 2025 | N/A |
| Dec 31, 2024 | -$0.11 | -$0.20 | -$0.28 - -$0.13 | +44.81% | Beat | N/A | 3 | N/A | Mar 13, 2025 | $5.96M |
| Sep 30, 2024 | -$6.60 | -$0.04 | N/A | N/A | N/A | N/A | 5 | 0 up, 0 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$4.40 | -$5.91 | -$6.40 - -$4.80 | +25.55% | Beat | -161.1% | 6 | 0 up, 1 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$5.40 | -$7.25 | -$8.60 - -$5.20 | +25.52% | Beat | N/A | 6 | 0 up, 0 down | May 8, 2024 | N/A |
| Dec 31, 2023 | -$0.32 | -$0.50 | -$1.00 - -$0.33 | +36.00% | Beat | N/A | 7 | 1 up, 0 down | Mar 5, 2024 | N/A |
| Sep 30, 2023 | -$7.40 | -$10.65 | -$13.40 - -$7.60 | +30.52% | Beat | N/A | 7 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | $7.20 | $10.97 | $9.00 - $14.80 | -34.37% | Miss | N/A | 7 | 1 up, 0 down | Aug 8, 2023 | $126.47M |
| Mar 31, 2023 | -$11.40 | -$10.85 | -$12.80 - -$9.00 | -5.07% | Miss | N/A | 8 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.54 | -$0.46 | -$0.55 - -$0.30 | -17.39% | Miss | N/A | 8 | 0 up, 0 down | Mar 7, 2023 | N/A |
| Sep 30, 2022 | -$9.80 | -$9.44 | -$11.00 - -$6.00 | -3.81% | Miss | -168.1% | 8 | 0 up, 0 down | Nov 2, 2022 | $3.44M |
| Jun 30, 2022 | -$14.00 | -$12.30 | -$13.00 - -$9.20 | -13.82% | Miss | N/A | 8 | 0 up, 0 down | Aug 3, 2022 | $1.22M |
| Mar 31, 2022 | -$12.20 | -$10.04 | -$12.40 - -$7.20 | -21.51% | Miss | N/A | 8 | 0 up, 0 down | May 4, 2022 | $1.49M |
| Dec 31, 2021 | -$0.52 | -$0.44 | -$0.62 - -$0.03 | -18.18% | Miss | N/A | 9 | N/A | Mar 1, 2022 | $7.22M |
| Sep 30, 2021 | $14.40 | -$3.46 | N/A | +516.18% | Beat | N/A | 7 | N/A | Nov 10, 2021 | $126.72M |
| Jun 30, 2021 | -$10.60 | -$7.63 | -$8.80 - -$5.80 | -38.93% | Miss | N/A | 9 | N/A | Aug 3, 2021 | $5.26M |
| Mar 31, 2021 | -$7.80 | -$6.30 | -$7.60 - -$4.60 | -23.81% | Miss | N/A | 6 | N/A | May 4, 2021 | $5.72M |
| Dec 31, 2020 | -$0.23 | -$0.28 | -$0.34 - -$0.20 | +17.86% | Beat | N/A | 8 | N/A | Mar 2, 2021 | $17.56M |
| Sep 30, 2020 | -$7.20 | -$5.00 | -$7.00 - -$4.00 | -44.00% | Miss | N/A | 7 | N/A | Nov 9, 2020 | $1.42M |
| Jun 30, 2020 | -$5.60 | -$5.16 | -$5.80 - -$4.40 | -8.53% | Miss | N/A | 7 | N/A | Jul 28, 2020 | $6.04M |
| Mar 31, 2020 | -$0.28 | -$0.28 | -$0.36 - -$0.24 | 0.00% | In line | N/A | 5 | N/A | May 7, 2020 | $8.19M |
| Dec 31, 2019 | -$5.00 | -$5.27 | -$7.80 - -$4.40 | +5.12% | Beat | N/A | 6 | N/A | Mar 2, 2020 | $7.62M |
| Sep 30, 2019 | -$4.60 | -$5.27 | -$11.20 - -$4.20 | +12.71% | Beat | N/A | 7 | N/A | Nov 5, 2019 | $7.03M |
| Jun 30, 2019 | -$4.80 | -$10.35 | -$12.80 - -$8.00 | +53.62% | Beat | N/A | 8 | N/A | Aug 6, 2019 | $12.53M |
| Mar 31, 2019 | -$11.13 | -$9.20 | -$14.40 - $4.20 | -20.98% | Miss | N/A | 7 | N/A | May 2, 2019 | $7.32M |
| Dec 31, 2018 | -$0.52 | -$0.50 | -$0.78 - $0.24 | -4.00% | Miss | N/A | 6 | N/A | Mar 6, 2019 | $10.63M |
| Sep 30, 2018 | -$10.80 | -$10.92 | -$15.60 - -$4.60 | +1.10% | Beat | N/A | 7 | N/A | Nov 8, 2018 | $9.05M |
| Jun 30, 2018 | -$13.60 | -$14.00 | -$15.80 - -$2.00 | +2.86% | Beat | N/A | 7 | N/A | Aug 2, 2018 | $4.61M |
| Mar 31, 2018 | -$13.80 | -$15.25 | -$16.00 - -$14.40 | +9.51% | Beat | N/A | 6 | N/A | May 9, 2018 | $3.97M |
| Dec 31, 2017 | -$0.72 | -$0.75 | -$0.81 - -$0.68 | +4.00% | Beat | N/A | 6 | N/A | Mar 8, 2018 | $3.06M |
| Sep 30, 2017 | -$3.40 | -$9.90 | -$16.80 - -$4.00 | +65.66% | Beat | N/A | 9 | N/A | Nov 8, 2017 | $23.02M |
| Jun 30, 2017 | -$13.80 | -$12.76 | -$15.60 - -$8.60 | -8.15% | Miss | N/A | 6 | N/A | Aug 3, 2017 | $3.01M |
| Mar 31, 2017 | -$12.60 | -$13.13 | N/A | +4.04% | Beat | N/A | N/A | N/A | May 4, 2017 | $3.02M |
| Dec 31, 2016 | -$0.63 | -$0.72 | N/A | +12.50% | Beat | N/A | N/A | N/A | Mar 16, 2017 | $3.04M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.33, after -$16.51 the year before. It was -$33.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.33 | N/A |
| Dec 31, 2024 | -$16.51 | N/A |
| Dec 31, 2023 | -$11.92 | N/A |
| Dec 31, 2022 | -$36.54 | N/A |
| Dec 31, 2021 | -$4.52 | N/A |
| Dec 31, 2020 | -$13.31 | N/A |
| Dec 31, 2019 | -$25.53 | N/A |
| Dec 31, 2018 | -$38.72 | N/A |
| Dec 31, 2017 | -$30.52 | N/A |
| Dec 31, 2016 | -$33.83 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 2,800 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q3 | Sep 30, 2025 | 2,779 | 8 | |
| 2025Q2 | Jun 30, 2025 | 2,617 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,899 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,972 | 12 | |
| 2024Q3 | Sep 30, 2024 | 4,581 | 10 | |
| 2024Q2 | Jun 30, 2024 | 4,817 | 10 |
2025Q3 Earnings Call
Opening remarks
Carlo Tanzi Investor Relations Thank you, and good morning. Today, before the market opened, we issued a press release with our third quarter 2025 financial results and business updates available on the Investors and News section of our website. We've also posted an updated corporate presentation. Before we begin, I'd like to remind everyone that we will be making forward-looking statements, including statements around the results of our current or planned clinical trials, studies and data readouts, our product candidates and their potential benefits, development plans and potential commercial opportunities, interactions with and feedback from the FDA, our ability to secure an R&D or other partnership and/or generate or obtain additional capital, financing or other resources, our planned strategic focus and operating plans, cost reduction actions and anticipated benefits and cash runway, the timing of any of the foregoing and other statements which are not historical facts. Actual results may differ materially due to various risks and uncertainties and other important factors described under Risk Factors in our recent SEC filings. We undertake no obligation to update these statements, except as required by law. On today's call with prepared remarks are Marella Thorell, our Co-Chief Executive Officer and Chief Financial Officer; and Dr. Matthew Henn, our Chief Scientific Officer. Additional members of the management team, including Tom DesRosier, Co-CEO and Chief Legal Officer; Terri Young, Chief Commercial and Strategy Officer; and Dr. Dennis Walling, SVP of Clinical Development, will be available during the Q&A portion of the call. And with that, I'll turn the call over to Marella.
Marella Thorell Co-CEO and CFO Thank you, Carlo, and good morning, everyone. We made good progress during the quarter. Our immediate priority remains advancing SER-155, our lead investigational, oral, live biotherapeutic for the prevention of bloodstream infections, or BSIs, in adults undergoing allo-HSCT into a Phase II study. We believe that results in this study, if positive, could represent a very meaningful value creation event for the company. SER-155 represents a first-in-class mechanistically differentiated approach to address infections, including bloodstream and antimicrobial resistant infections, which are among the causes of mortality in medically compromised patients. In the Phase Ib study, treatment with SER-155 led to an impressive 77% relative risk reduction in bacterial bloodstream infections, along with decreased antibiotic exposure and febrile neutropenia. The therapy is designed to decolonize gastrointestinal pathogens, improve epithelial barrier integrity and restore immune balance, addressing root causes to prevent BSIs and therefore, reduce antibiotic use, antimicrobial resistance and often severe or fatal outcomes. Based on our analysis of the commercial opportunity, we believe that SER-155 could transform how allo-HSCT patients are managed and result in meaningfully improved patient outcomes.
Frequently Asked Questions About MCRB
When is Seres Therapeutics's next earnings date?
Seres Therapeutics's next earnings report is expected for Mar 10, 2027.
Did MCRB beat earnings estimates last quarter?
Yes. Seres Therapeutics reported EPS of -$1.06 for the quarter ended Sep 30, 2026, above the -$1.34 estimate, a 20.90% surprise.
What EPS do analysts expect from MCRB next quarter?
The consensus EPS estimate for Seres Therapeutics for the quarter ending Dec 31, 2026 is -$0.66 from 4 analysts, with estimates from -$1.53 to $0.28.
How often does MCRB beat earnings estimates?
Seres Therapeutics beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -14.44%.
MCRB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors